In its board meeting held on May 22, 2026, Sun Pharmaceutical Industries Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a revenue from operations of 49,238.8 Millions for the quarter. The Profit After Tax (PAT) for the same period was recorded at 6,087.0 Millions.

Note: Comparative analysis (QoQ and YoY) requires historical data not fully available in the current disclosure; percentages are omitted to ensure accuracy.

Sun Pharmaceutical Industries Limited is a leading global specialty generic pharmaceutical company, headquartered in Mumbai, India. It provides high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries. As of 2025, the company has maintained a strong focus on expanding its specialty portfolio and enhancing its presence in key global markets, including the United States and emerging economies. Recent updates indicate a continued commitment to research and development, with significant investments directed toward complex generics and biosimilars to drive long-term growth.

The company’s financial performance reflects its strategic execution in a competitive global landscape. For the quarter ended March 31, 2026, the company recorded a profit before tax of 8,490.1 Millions. The board has also recommended a final dividend of 5 per equity share of 1 each for the financial year 2025-26, subject to shareholder approval at the upcoming 34th Annual General Meeting. Sun Pharma continues to be a significant entity for institutional investors, with its consistent track record in the pharmaceutical sector.